Intellectual Product

Recent news on Biopharma Sentiment Index (BPSI)

2 days ago talkbio0Tagged Attitude, Biopharma, Biopharma Sentiment Index, BPSI, drug development sentiment, Endpoints, investing, News [Publication Type], Pharma Industry, Sentiment

Biopharma Sentiment Index; BPSI; Endpoints News; biopharma sentiment survey; drug development sentiment; biotech investing sentiment; pharma industry outlook

Former FDA Chiefs Criticize Proposed Vaccine Policy Changes at ACIP Meeting

3 days ago talkbio0Tagged * New England Journal of Medicine*., ACIP, Centers for Disease Control and Prevention (U.S.), Changing, commissioners, COVID19 (disease), Policy, research, Senator Bill Cassidy, United States Food and Drug Administration, vaccine safety regulation, Vaccines, Vinay Prasad ; Center for Biologics Evaluation

former FDA commissioners; CDC; ACIP meeting; vaccine policy changes; COVID-19 vaccines; Vinay Prasad; Center for Biologics Evaluation and Research; vaccine safety regulation; Senator Bill Cassidy; New England Journal of Medicine commentary

mAbxience and HP Drive the Use of Artificial Intelligence in Biomanufacturing and Biosimilar Development

4 days ago talkbio0Tagged Artificial Intelligence, Biological Factors, biomanufacturing, Biosimilars, development aspects, digital twin, Fresenius, Hereditary pancreatitis, mAbxience, Monoclonal Antibodies, Neural Network Simulation

mAbxience; HP; artificial intelligence; biomanufacturing; biosimilar development; digital twin; monoclonal antibodies; neural network models; biologics; Fresenius

MediView Achieves First CE Mark, Bringing Augmented Reality to European Healthcare

6 days ago talkbio0Tagged augmented, Augmented Reality, CE Mark, clinical visualization, European (ethnic group), GE HealthCare, Health care facility, Interventional radiology, MediView, MediView XR, MediView XR90, reality

MediView; CE Mark; augmented reality; European healthcare; mixed reality; clinical visualization; MediView XR; MediView XR90; GE Healthcare; interventional radiology

Recent Developments in Medical Affairs Reputation and Hemophilia A Management in the US (2025)

6 days ago talkbio0Tagged Acquired (qualifier value), Centers for Disease Control and Prevention (U.S.), federal funding, gene therapy, Health Policy, Hemophilia A, Hemophilia A Pipeline, Hemophilia Treatment Centers, HRSA, Medical Affairs, Programs - Publication Format, public health policy, reputation, U.S.

Medical Affairs; Reputation; Hemophilia A; US; 2025; Gene Therapy; Public Health Policies; Hemophilia Treatment Centers; 340B Program; Federal Funding; Acquired Hemophilia A Pipeline; Healthcare Policy; CDC; HRSA

White House Requests Resignation of Top FDA Aide, Prompting Tensions with Commissioner Makary

2 weeks ago talkbio0Tagged CHARGE Syndrome, controversy, internal tensions, management technique, Marty Makary, resignation, Sanjula Jain-Nagpal, United States Food and Drug Administration, White House, Workforce - population group

FDA; White House; Marty Makary; Sanjula Jain-Nagpal; resignation; HHS; staffing controversy; Robert F. Kennedy Jr.; management style; internal tensions

FDA Breakthrough Designations Lead to Priority Reviews, Report Finds

2 weeks ago talkbio0Tagged biotechnology innovation, Breakthrough Therapy, CDER, Drug Approval, expedited pathway, Identifier, Infrequent, Neoplasms, Priority Review, regulatory science, United States Food and Drug Administration

FDA; breakthrough therapy designation; priority review; drug approval; expedited pathway; biotechnology innovation; rare diseases; oncology; CDER; regulatory science

Edgewise Therapeutics Appoints Christopher Martin to its Board of Directors

2 weeks ago talkbio0Tagged Acquisition, Becker Muscular Dystrophy, board of directors, cardiovascular asset, Christopher Martin, commercial, Edgewise Therapeutics, executives, Leadership, Merck, Verona Pharma

Edgewise Therapeutics; Christopher Martin; Board of Directors; biotech executive; commercial leadership; Becker muscular dystrophy; cardiovascular asset; Verona Pharma; Merck acquisition

EDAP Receives FDA 510(k) Clearance for Advanced Focal One Robotic HIFU System Enhancements

2 weeks ago talkbio0Tagged algorithm, Clearance, Edap, Malignant neoplasm of prostate, Medical Devices, robotic HIFU, United States Food and Drug Administration

EDAP; FDA 510(k) clearance; Focal One; robotic HIFU; high intensity focused ultrasound; ultrasound imaging; prostate cancer treatment; AI algorithms; medical devices

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib in TKI Pre-treated Advanced ROS1-positive NSCLC

2 weeks ago talkbio0Tagged acceptance, ARROS-1 trial, Breakthrough Therapy, Clinical Nurse Specialists, Identifier, New Drug Application, Non-Small Cell Lung Carcinoma, Nuvalent, orphan drug designation, PDUFA, Penetration, pre-treated, Protein-tyrosine kinase inhibitor, ROS1-positive, United States Food and Drug Administration, zidesamtinib

Nuvalent; zidesamtinib; FDA acceptance; New Drug Application (NDA); ROS1-positive NSCLC; tyrosine kinase inhibitor (TKI) pre-treated; ARROS-1 trial; PDUFA date; CNS penetration; breakthrough therapy designation; orphan drug designation